Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

AIR STUDY

TITLE: Anti-Ischemic effects of Abciximab(Reopro)

PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).

INTERVENTION: Heparin vs. heparin + abciximab during PCI

PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.

PATIENT ASSESSMENT:

1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28. 2. Measurement of blood flow in selected suitable patients 3. 10 minute questionnaire before discharge and on visit on day 28.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Atlanta VA Medical Center, Atlanta, Georgia, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Have either:

clinical history of anginal symptoms or positive stress test or
in stent restenosis
Have an angiographic >70% coronary artery stenosis that will be treated with coronary angioplasty or stenting procedure
For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase inhibitor or a stable statin dose
negative pregnancy test
are able to give informed consent

Exclusion criteria

Coronary intervention within four weeks prior to enrollment.
Treatment with abciximab antagonist within four weeks.
treatment with thrombolytic therapy within 48 hours
MI within 2 months.
recent infections
general anesthesia within 3 months.
renal failure

Treatment and study plan

Abciximab

Drug

Other names: Reopro

Sponsors and collaborators

Lead sponsor

Emory University

Other

Registry information

Official study title

Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)

Acronym: AIR

Important dates

Study start: 2003
Primary completion: 2009
Study completion: 2009
First posted: Sep 21, 2006
Registry last updated: Sep 12, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed